- Home
- CHN vs KPTI Comparison
CHN vs KPTI Comparison
Compare CHN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- KPTI
- Stock Information
- Founded
- CHN 1992
- KPTI 2008
- Country
- CHN United States
- KPTI United States
- Employees
- CHN N/A
- KPTI N/A
- Industry
- CHN Investment Managers
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- CHN Finance
- KPTI Health Care
- Exchange
- CHN Nasdaq
- KPTI Nasdaq
- Market Cap
- CHN 107.2M
- KPTI 90.7M
- IPO Year
- CHN N/A
- KPTI 2013
- Fundamental
- Price
- CHN $11.39
- KPTI $0.66
- Analyst Decision
- CHN
- KPTI Strong Buy
- Analyst Count
- CHN 0
- KPTI 4
- Target Price
- CHN N/A
- KPTI $5.00
- AVG Volume (30 Days)
- CHN 31.8K
- KPTI 1.0M
- Earning Date
- CHN 01-01-0001
- KPTI 02-27-2025
- Dividend Yield
- CHN 0.19%
- KPTI N/A
- EPS Growth
- CHN N/A
- KPTI N/A
- EPS
- CHN N/A
- KPTI N/A
- Revenue
- CHN N/A
- KPTI $148,442,000.00
- Revenue This Year
- CHN N/A
- KPTI $6.67
- Revenue Next Year
- CHN N/A
- KPTI $8.58
- P/E Ratio
- CHN N/A
- KPTI N/A
- Revenue Growth
- CHN N/A
- KPTI 1.77
- 52 Week Low
- CHN $9.00
- KPTI $0.58
- 52 Week High
- CHN $12.98
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- CHN 43.48
- KPTI 44.20
- Support Level
- CHN $11.12
- KPTI $0.61
- Resistance Level
- CHN $11.33
- KPTI $0.73
- Average True Range (ATR)
- CHN 0.27
- KPTI 0.08
- MACD
- CHN -0.04
- KPTI -0.00
- Stochastic Oscillator
- CHN 33.33
- KPTI 26.13
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.